KEYNOTE-057
KEYNOTE-057 showed that pembrolizumab could clear bladder cancer confined to the lining in a substantial minority of people whose disease had stopped responding to BCG, giving the first drug alternative to removing the bladder.
Overview
After BCG fails in high-risk non-muscle-invasive bladder cancer the standard is radical cystectomy, which many patients decline or cannot have. KEYNOTE-057 was a single-arm phase 2 study of pembrolizumab in BCG-unresponsive disease. Cohort A enrolled patients with carcinoma in situ with or without papillary tumours, with complete response rate as the primary endpoint; cohort B enrolled papillary-only high-grade disease, with disease-free survival as the endpoint.
In cohort A a substantial minority achieved a complete response at three months and about half of those responses lasted a year or more, with a systemic immunotherapy toxicity profile. Pembrolizumab was approved in the United States in January 2020 for BCG-unresponsive carcinoma in situ, the first systemic drug for this setting, followed by nadofaragene firadenovec and nogapendekin alfa inbakicept as bladder-sparing alternatives.
Similar pages
not linked directly; found by shared links- TrialKEYNOTE-412
Shares Merck & Co. (MSD), Pembrolizumab and the tag subtype-trials.
- TrialKEYNOTE-407
Shares Merck & Co. (MSD), Pembrolizumab and the tag subtype-trials.
- TrialSARC028
Shares Merck & Co. (MSD), Pembrolizumab and the tag subtype-trials.
- TrialKEYNOTE-062
Shares Merck & Co. (MSD), Pembrolizumab and the tag subtype-trials.
- TrialKEYNOTE-811
Shares Merck & Co. (MSD), Pembrolizumab and the tag subtype-trials.
- TrialSTAMP (EA6174)
Shares Pembrolizumab and the tag subtype-trials.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Shares Non-muscle-invasive bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab.
- TrialA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Shares Non-muscle-invasive bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer.